Randomized trial · 2006

Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome.

RS Lucidi, AC Thyer, CA Easton, AE Holden, RS Schenken, RG Brzyski. Fertility and sterility.

In women with polycystic ovary syndrome, chromium picolinate (200 microg/d) improves glucose tolerance compared with placebo but does not improve ovulatory frequency or hormonal parameters. This pilot study indicates that future studies in the polycystic ovary syndrome population should examine higher dosages or longer durations of treatment.

Open source PMID 16359984

Edges that cite this paper

Jamilian 2016 found that 200 micrograms of chromium picolinate a day for eight weeks moved HOMA-IR by -0.8 versus +0.9 on placebo in 64 women with polycystic ovary syndrome (P<0.001). Kim 2012 saw a similar direction in 25 overweight children. Jain 2013's picolinate arm did not.

Cite this page

What Causes What. “Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome..” https://whatcauseswhat.org/papers/p-pmid-16359984 (atlas updated 2026-09-02).

https://whatcauseswhat.org/papers/p-pmid-16359984